UCSF researchers move closer to predicting sudden infant death syndrome

Researchers at UC San Francisco are getting closer to being able to predict sudden infant death syndrome, or SIDS.

Mirum’s maralixibat oral secures approval from Health Canada

LIVMARLI has been now authorised in Canada to treat cholestatic pruritus in patients with Alagille syndrome. Credit: Shidlovski /Shutterstock.com. Mirum Pharmaceuticals has received approval from

July 26, 2023

How a major hospital shows just how inflated hospital list prices are

Hospitals’ list prices for surgeries, therapies, and other procedures always come with massive discounts. Financial documents at a prominent hospital system in Los Angeles show

November 20, 2023

Hawthorne Gardening Q2 Revenue Plunges 30% Sequentially to $92.7…

ScottsMiracle-Gro Reports Fiscal 2023 Second Quarter Results U.S. Consumer First Half Sales of $1.73B in Line with Record Prior Two Years Fiscal 2Q23 GAAP EPS

May 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.